TickerTalks
Browse all tickers →
TickerTalks›$CUE
CUCUE

Cue Biopharma, Inc.

$CUE·$71M·Biotechnology·Healthcare
$26.84-11.7%YTD+227.6%1Y+19.2%
Mentions · last 7 days
2026-07-26: 4 posts2026-07-27: 6 posts2026-07-28: 4 posts2026-07-29: 3 posts2026-07-30: 8 posts2026-07-31: 9 posts2026-08-01: 0 posts34+36%
Price updated 1d ago·X counts updated 2h ago
CUCUE
$CUECue Biopharma, Inc.
$26.84-11.71%34 posts+36%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CUE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventCooling offAI verdict · as of 2026-08-01

Catching its breath after a run — could pick back up or fade from here.

Cue Biopharma up 228% YTD — $50M private placement at $33.21 (300% higher than prior), Aug 18 print.

Cue Biopharma is a clinical-stage biotech developing CUE-221 (dual-MOA anti-IgE) and other immuno-oncology assets. Up 228% YTD but only 19% over 12 months — the recent gain reflects a specific catalyst: the July 9 $50M private placement priced at $33.21 (roughly 300% higher than the prior placement a few months ago) validated at high institutional prices.

Where the setup sits:

  • The $50M private placement is the substantive capital event: priced at $33.21 with no warrants attached, led by Cormorant Asset Management with new participation from Columbia Threadneedle — this is exceptionally strong institutional validation.
  • The CUE-221 China Phase 2 CSU readout is the specific catalyst: dual-MOA anti-IgE described as higher-potency Xolair with higher-BMI exposure — this is what supports the equity story.
  • Q1 was a modest beat: EPS negative $1.08 vs negative $3.30 consensus on $10M revenue (+1,251% YoY) — the growth is off a tiny base but directionally positive.
  • Q2 print date August 18: multiple insider awards this month plus the CMO/R&D head appointment (Dominique Borie) signal continued strategic build-up.

August 18 is the pivot: continued CUE-221 clinical progress plus firm 2027 China Phase 2 readout timing is what breaks the current cooling; a competitive anti-IgE data setback or a Taiwan/China patient-population generalizability concern and the +228% YTD gives back significant ground.

Agrees with X sentimentX captures the substance — the $50M private placement at $33.21 (300% higher than the prior placement) led by Cormorant Asset Management with new participation from Columbia Threadneedle and no warrants attached, the CUE-221 dual-MOA anti-IgE with higher-BMI exposure, and the honest Momentum-Letter short recommendation plus Taiwan/China patient-population generalizability caveat are all real.

What to watch: The August 18 Q2 print — continued CUE-221 clinical progress plus firm 2027 China Phase 2 readout timing breaks the current cooling; competitive anti-IgE data setback or Taiwan/China generalizability concern and the +228% YTD gives back ground.

On the calendar: 2026-08-18 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment13 posts analyzed · as of 2026-07-17

Cue Biopharma just closed a $50M private placement priced at $33.21 per share (with pre-funded warrants), led by Cormorant Asset Management with new participation from Columbia Threadneedle, at a price roughly 300% higher than the previous private placement a few months ago - a strong validation signal. Bulls emphasize the completion with no warrants attached and see this as positioning for the upcoming China Phase 2 CSU readout for CUE-221 (a dual-MOA anti-IgE described as higher-potency Xolair with higher-BMI exposure). The stock opened around $40.57 with an intraday high of $45.52 before pulling back to about $38.75. The main critical thread is a Momentum-Letter short recommendation and a note that Taiwan/China patient population interpretation may not fully generalize outside those markets.

Read the AI verdict + X sentiment for $CUE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing fusion protein immunotherapies (CUE-101) to activate T cells against HPV-driven cancers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CUE.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $CUE

Neutral — Clinical-stage biotech developing fusion protein immunotherapies (CUE-101) to activate T cells against HPV-driven cancers; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-78.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-59.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-35.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-98.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-1.08$-3.30+67.3%
Q4 2025Mar 16, 2026$0.30$-2.70+111.1%
Q3 2025Nov 12, 2025$-0.07$-0.10+30.0%
Q2 2025Aug 12, 2025$-0.09$-0.13+30.8%
Next earningsTue, Aug 18·consensus EPS $-1.69

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$5.7M+1250.6%100%-94.3%$-1.08$-11.1M
Q4 FY25$21.9M+1292.3%100%8.9%$0.44$-1.1M
Q3 FY25$2.1M-35.6%96.3%-351%$-2.21$-9.0M
Q2 FY25$3.0M+11.1%100%-292%$-2.66$-3.4M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.8M$12.8M – $12.8M-$6.64-$6.64 – -$6.641
FY27$1.0M$1.0M – $1.0M-$9.45-$9.45 – -$9.451
FY28$1.0M$1.0M – $1.0M-$15.30-$15.30 – -$15.301
FY29$1.0M$1.0M – $1.0M-$15.60-$15.60 – -$15.601

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.54%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+48.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 2.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today18.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.465-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 1Shao-lee LinCEO136.4K sh$500K
+ 15 other (15 awards) in window

See when $CUE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 153
AI summary

Dominique Christian Borie filed an initial Form 3 on July 15, 2026, disclosing no beneficially owned securities of Cue Biopharma (CUE). Borie joined Cue Biopharma as Chief Medical Officer and Head of Research & Development, with an effective date of July 13, 2026. This filing initiates Borie's reporting obligations as an officer under Section 16(a) of the Securities Exchange Act.

8-KMaterial agreementJul 108-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

Cue Biopharma, Inc. closed a $50 million private placement on July 9, 2026, issuing 1,418,071 shares of common stock at $33.21/share plus pre-funded warrants for up to 87,500 shares at $33.209 each, to accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. The offering was unregistered (private placement) with securities subject to resale registration requirements. This is a dilutive $50M financing event for a clinical-stage biopharma — institutional participation from Cormorant and Columbia Threadneedle signals credible demand and provides runway for pipeline advancement.

S-3Shelf registrationJun 18S-3
AI summary

Cue Biopharma (CUE) filed a Form S-3 shelf registration statement on June 18, 2026, signed by CEO Shao-Lee Lin. The registration covers future securities offerings; the specific aggregate offering amount was not disclosed in the excerpt. This is a routine shelf filing enabling future capital raises.

3New insider — initial holdingsJun 113
AI summary

Michael Vincent Meluzio filed a Form 3 on June 1, 2026, as a newly appointed officer of Cue Biopharma, Inc. (CUE), serving as VP and Principal Accounting Officer, reporting no direct or indirect securities owned at the time of filing. This is a routine initial ownership disclosure for a new finance executive with no immediate financial impact.

3New insider — initial holdingsJun 113
AI summary

Sumita Ray filed a Form 3 on June 1, 2026, as a newly appointed officer of Cue Biopharma, Inc. (CUE), serving as Chief Legal & Compliance Officer and Corporate Secretary, reporting direct ownership of 54,589 shares of common stock. This is a routine initial ownership statement for a new executive appointment with no financial impact on the company.

3New insider — initial holdingsJun 83
AI summary

Daniel A. Camardo filed a Form 3 on May 30, 2026, as a newly appointed Director of Cue Biopharma, Inc. (CUE), reporting no direct or indirect securities owned at the time of the filing. This is a routine initial ownership disclosure for a new board member with no financial impact on the company.

8-KOfficer or director changeJun 38-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Cue Biopharma, Inc. filed an 8-K on June 3, 2026 covering Items 5.02 (officer/director change) and 5.07 (shareholder vote results) from the June 1, 2026 annual meeting. The excerpt is boilerplate header only; specific vote tallies and the nature of the director/officer change are in the attached exhibits. The combination of 5.02 and 5.07 suggests a director election or departure was among the annual meeting agenda items — a routine governance event.

S-3Shelf registrationJun 3S-3
AI summary

Cue Biopharma, Inc. (Boston, CEO Shao-Lee Lin) filed an S-3 shelf registration statement on June 3, 2026, registering securities for offer and sale on a delayed or continuous basis under Rule 415. The total dollar amount being registered is not stated in the excerpt; it would appear in the prospectus body or a subsequent supplement. Filed the same day as the annual meeting 8-K, this shelf registration establishes future fundraising capacity — not immediate dilution, but a signal the company is positioning to access capital markets.

+ 30 other (6 8-Ks · 3 EFFECTs · 3 proxys · 2 Ds) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Developmentglobenewswire.com·20d agoCue Biopharma Announces $50.0 Million Private Placementglobenewswire.com·23d agoCue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolutionglobenewswire.com·60d agoCue Biopharma to Present at the 2026 Jefferies Global Healthcare Conferenceglobenewswire.com·72d agoCue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developmentsglobenewswire.com·79d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport